Zhongcao Wei1, Na Liu2, Xinxing Tantai1, Xin Xing1, Cailan Xiao1, Lirong Chen1, Jinhai Wang3. 1. Department of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157, Xi Wu Road, Xi'an, Shanxi, People's Republic of China. 2. Department of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157, Xi Wu Road, Xi'an, Shanxi, People's Republic of China. liunafmmu@163.com. 3. Department of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157, Xi Wu Road, Xi'an, Shanxi, People's Republic of China. jinhaiwang@hotmail.com.
Abstract
AIMS: Evidence indicates that curcumin seems to improve outcomes in non-alcoholic fatty liver disease (NAFLD). A meta-analysis was performed to evaluate the effects of curcumin inNAFLD. METHODS: We searched PubMed, EMBASE, and the Cochrane Library from inception through March 2018 to identify randomized controlled trials (RCTs) evaluating the role of curcumin inNAFLD. The mean difference (MD) and 95% confidence interval (CI) were calculated. RESULTS: Four RCTs with a total of 229 NAFLD patients were included. Curcumin was more likely to lower LDL-C, triglycerides, FBS, HOMA-IR, weight and AST levels compared with placebo, and the difference was statistically significant [MD = - 27.02, 95% CI (- 52.30, - 1.74); MD = - 33.20, 95% CI (- 42.30, - 24.09); MD = - 5.63, 95% CI (- 10.36, - 0.90); MD = - 0.53, 95% CI (- 1.00, - 0.05); MD = - 2.27, 95% CI (- 3.11, - 1.44); MD = - 7.43, 95% CI (- 11.31, - 3.54), respectively]. However, the beneficial effect of curcumin did not achieve statistical significance in lowering total cholesterol, HDL-C, HbA1c, ALT or insulin levels [MD = - 30.47,95% CI (- 60.89. - 0.06); MD = - 0.98, 95% CI (- 2.88, 0.92); MD = - 0.41, 95% CI (- 1.41, 0.59); MD = - 6.02, 95% CI (- 15.61, 3.57); MD = - 0.92, 95% CI (- 2.33, 0.49)]. CONCLUSIONS: Curcumin is effective in lowering LDL-C, triglycerides, FBS, HOMA-IR, weight, and AST levels in NAFLD patients, and it is well tolerated. Further RCTs are required to confirm our findings.
AIMS: Evidence indicates that curcumin seems to improve outcomes in non-alcoholic fatty liver disease (NAFLD). A meta-analysis was performed to evaluate the effects of curcumin inNAFLD. METHODS: We searched PubMed, EMBASE, and the Cochrane Library from inception through March 2018 to identify randomized controlled trials (RCTs) evaluating the role of curcumin inNAFLD. The mean difference (MD) and 95% confidence interval (CI) were calculated. RESULTS: Four RCTs with a total of 229 NAFLD patients were included. Curcumin was more likely to lower LDL-C, triglycerides, FBS, HOMA-IR, weight and AST levels compared with placebo, and the difference was statistically significant [MD = - 27.02, 95% CI (- 52.30, - 1.74); MD = - 33.20, 95% CI (- 42.30, - 24.09); MD = - 5.63, 95% CI (- 10.36, - 0.90); MD = - 0.53, 95% CI (- 1.00, - 0.05); MD = - 2.27, 95% CI (- 3.11, - 1.44); MD = - 7.43, 95% CI (- 11.31, - 3.54), respectively]. However, the beneficial effect of curcumin did not achieve statistical significance in lowering total cholesterol, HDL-C, HbA1c, ALT or insulin levels [MD = - 30.47,95% CI (- 60.89. - 0.06); MD = - 0.98, 95% CI (- 2.88, 0.92); MD = - 0.41, 95% CI (- 1.41, 0.59); MD = - 6.02, 95% CI (- 15.61, 3.57); MD = - 0.92, 95% CI (- 2.33, 0.49)]. CONCLUSIONS:Curcumin is effective in lowering LDL-C, triglycerides, FBS, HOMA-IR, weight, and AST levels in NAFLD patients, and it is well tolerated. Further RCTs are required to confirm our findings.
Authors: R A Sharma; H R McLelland; K A Hill; C R Ireson; S A Euden; M M Manson; M Pirmohamed; L J Marnett; A J Gescher; W P Steward Journal: Clin Cancer Res Date: 2001-07 Impact factor: 12.531
Authors: David Tendler; Sauyu Lin; William S Yancy; John Mavropoulos; Pam Sylvestre; Don C Rockey; Eric C Westman Journal: Dig Dis Sci Date: 2007-01-12 Impact factor: 3.199
Authors: Amin A Nanji; Kalle Jokelainen; George L Tipoe; Amir Rahemtulla; Peter Thomas; Andrew J Dannenberg Journal: Am J Physiol Gastrointest Liver Physiol Date: 2002-08-28 Impact factor: 4.052
Authors: Luis E Simental-Mendía; Claudia I Gamboa-Gómez; Fernando Guerrero-Romero; Mario Simental-Mendía; Adriana Sánchez-García; Mariana Rodríguez-Ramírez Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622
Authors: Mohammad Bagherniya; Mina Darand; Gholamreza Askari; Paul C Guest; Thozhukat Sathyapalan; Amirhossein Sahebkar Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622